FBTCX (Fidelity Adv Biotech;C)
Net Asset Value: 12.44
1-Day Return:
0.06 (0.48%)
YTD Return as of 4/4/13: 19.04%
Classification: Health/Biotech Objective: Health/Biotech Open to New Investors: Yes
Lipper Rating
The Lipper Leader system ranks a fund in the following categories: Total Return; Consistent Return; Preservation; Tax Efficiency; and Expenses. Funds are rated in ascending order on a numeric scale of 1 to 5, with '1' representing funds with the lowest rating, and '5' representing the highest rated funds and funds that are Lipper Leaders. Click here for more detail.
| Growth of $10,000
Key Numbers
| FBTCX | Class Average | |
| Price/Earnings Ratio | 30.63 | 26.33 |
| Price/Book Ratio | 8.43 | 5.42 |
| 1 Yr Earnings Growth | 15.64 | 14.59 |
| 5 Yr Earnings Growth | 31.96 | 14.73 |
| 3 Yr Sales Growth | 17.64 | 14.21 |
| 5 Yr Sales Growth | 31.89 | 20.61 |
| Avg. Market Cap ($Mil) | 23,086 | 43,479 |
| Yield | 0.00 | NA |
| Turnover Ratio | 82.00 | 122.63 |
| Number of Holdings | 148 | 81 |
| ROE | -38.31 | 0.65 |
| ROC | -61.46 | -4.82 |
Asset Allocation
The pie chart shows the breakdown of the top industries or bond classes held by this mutual fund.
Sector Weightings
The pie chart shows the breakdown of the fund's holdings by asset class.
Top Ten Holdings
| Company Name | % of Total | YTD Return |
|---|---|---|
| Amgen Inc Ord | 13.04 | 7.40 |
| Gilead Sciences Inc Ord | 13.00 | 18.30 |
| Biogen Idec Inc Ord | 6.98 | 15.26 |
| Regeneron Pharmaceuticals Inc Ord | 4.72 | 0.39 |
| Celgene Corp Ord | 4.46 | 34.60 |
| Onyx Pharmaceuticals Inc Ord | 4.08 | -0.37 |
| Medivation Inc Ord | 3.68 | -9.93 |
| Vertex Pharmaceuticals Inc Ord | 3.62 | 10.19 |
| Taxable Cent Cash Fd | 3.22 | NA |
| Alexion Pharmaceuticals Inc Ord | 2.23 | -7.44 |
| % of Total Holdings | 59.03 |
Manager
| Manager Name: Manager Tenure: | Rajiv Kaul 2005 |
|---|
